Edinburgh acquisition heralds Alzheimer’s treatment on the horizon

Published: 3 Sep 2014 05:30

SCOTLAND could be one step closer to the long-awaited treatment for Alzheimer’s disease now that an Australian biotechnology firm has acquired Edinburgh BioQuarter spin-out Corticrine Ltd.

It’s currently at the forefront of research and development when it comes to novel treatments for disease modification and prevention of Alzheimer’s dementia thanks to Corticrine – a mid-stage pharmaceutical company borne out of the commercialisation arm of the College of Medicine and Veterinary Medicine at the University of Edinburgh – whose acquisition will transform Australia’s Actinogen Ltd into a clinical-stage company with an asset which has the potential to become the coveted treatment for the dementia aspect of the disease.

Corticrine has licensed worldwide development and commercialisation rights to UE2323, which is in clinical development for the treatment of Alzheimer’s and has received considerable funding from the Wellcome Trust Seeding Drug Discovery programme.

Bill Blair, head of Business Creation at Edinburgh BioQuarter, said: "The acquisition of Corticrine by Actinogen allows access to significant amounts of capital to advance clinical development of UE2343 and to benefit from the considerable research incentives for novel drugs in Australia. The deal is indicative of the innovative approaches adopted by Edinburgh BioQuarter to commercialize novel IP from the University of Edinburgh's College of Medicine and Veterinary Medicine."

According to the World Health Organisation, 18 million people around the world are affected by Alzheimer's, including 5.1 million in the US alone – making it a multi-billion dollar market.

Jump to first paragraph.